The FDA has taken further action against Ranbaxy Laboratories Ltd. of India, following inspections between January 5 and 11, prohibiting it from manufacturing or selling drug ingredients from its Toansa, India plant for the U.S. market. Ranbaxy, a subsidiary of Japan’s Daiichi Sankyo Co., is a major supplier of raw materials for the generic drug market, including the U.S., and has been cited for a series of FDA violations in the past couple of years.   The FDA has blocked the company from ...